A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE

被引：0

作者：

Mantzaris, G. ^{[1
]}

Bressler, B. ^{[2
]}

Kopylov, U. ^{[3
]}

Bassel, M. ^{[4
]}

Brett, N. ^{[4
]}

Colby, C. ^{[5
]}

Lopez, C. ^{[6
]}

Saha, S. ^{[7
]}

Kifnidi, C. ^{[8
]}

Agboton, C. ^{[9
]}

Adsul, S. ^{[9
]}

Demuth, D. ^{[10
]}

Luo, M. ^{[11
]}

Wang, S. ^{[11
]}

Yarur, A. ^{[12
]}

机构：

[1] Evangelismos Med Ctr, Dept Gastroenterol, Athens, Greece

[2] St Pauls Hosp, Dept Gastroenterol, Vancouver, BC, Canada

[3] Sheba Med Ctr, Dept Gastroenterol, Tel Aviv, Israel

[4] Evidera, Real World Evidence, Montreal, PQ, Canada

[5] Evidera, Real World Evidence, San Francisco, CA USA

[6] Takeda Pharmaceut USA Inc, Dept Med Affairs, Deerfield, IL USA

[7] Takeda Canada Inc, Dept Med Affairs, Oakville, ON, Canada

[8] Takeda Hellas SA Athens, Dept Med Affairs, Athens, Greece

[9] Takeda Pharmaceut Int AG, Dept Global Med Affairs, Zurich, Switzerland

[10] Takeda Pharmaceut Int, Evidence Generat & Publicat, Singapore, Singapore

[11] Takeda Pharmaceut Int, Global Outcomes Res, Boston, MA USA

[12] Med Coll Wisconsin, Dept Gastroenterol, Milwaukee, WI 53226 USA

来源：

JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP55

引用

页码：S092 / S094

页数：3

共 50 条

[1] A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
Mantzaris, Gerassimos J.
Bressler, Brian
Kopylov, Uri
Bassel, Marielle
Brett, Neil R.
Colby, Chris
Lopez, Claudia
Saha, Sumit
Kifnidi, Christina
Agboton, Christian
Adsul, Shashi
Demuth, Dirk
Luo, Michelle
Wang, Song
Yarur, Andres J.
GASTROENTEROLOGY, 2020, 158 (06) : S405 - S405
[2] A real-world comparison of the effectiveness and safety of vedolizumab and anti-tumor necrosis factor therapies in early treatment initiation with first-line biological therapy in ulcerative colitis: Results from EVOLVE
Mantzaris, G.
Bressler, B.
Kopylov, U.
Bassel, M.
Colby, C.
Lopez, C.
Saha, S.
Kifnidi, C.
Agboton, C.
Adsul, S.
Demuth, D.
Luo, M.
Wang, S.
Yarur, A.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 119 - 120
[3] REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF IN BIOLOGIC-NAIVE ULCERATIVE COLITIS PATIENTS: RESULTS FROM THE EVOLVE STUDY
Yarur, Andres J.
Mantzaris, Gerassimos J.
Silverberg, Mark S.
Walshe, Margaret
Zezos, Petros
Stein, Dara
Bassel, Marielle
Lissoos, Trevor
Lopez, Claudia
Natsios, Athanasios
Radulescu, Gabriela
Patel, Haridarshan
Demuth, Dirk
Bressler, Brian
GASTROENTEROLOGY, 2019, 156 (06) : S637 - S638
[4] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
Yarur, A.
Mantzaris, G.
Silverberg, M.
Walshe, M.
Zezos, P.
Stein, D.
Bassel, M.
Lissoos, T.
Lopez, C.
Natsios, A.
Radulescu, G.
Patel, H.
Demuth, D.
Bressler, B.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S400 - S401
[5] Real World Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naive Ulcerative Colitis and Crohn's Disease Patients: Results From the EVOLVE Study
Yarur, Andres
Mantzaris, Gerassimos J.
Kopylov, Uri
Bassel, Marielle
Brett, Neil R.
Lissoos, Trevor
Lopez, Claudia
Natsios, Athanasios
Kifnidi, Christina
Saha, Sumit
Demuth, Dirk
Patel, Haridarshan
Bressler, Brian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S460 - S461
[6] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study
Bressler, B.
Mantzaris, G.
Silverberg, M.
Zezos, P.
Stein, D.
Colby, C.
Lissoos, T.
Lopez, C.
Natsios, A.
Radulescu, G.
Patel, H.
Demuth, D.
Yarur, A.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S427 - S428
[7] REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF IN BIOLOGIC-NAIVE CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
Mantzaris, Gerassimos J.
Yarur, Andres J.
Silverberg, Mark S.
Zezos, Petros
Stein, Dara
Kim, Hankyul
Lissoos, Trevor
Lopez, Claudia
Natsios, Athanasios
Radulescu, Gabriela
Patel, Haridarshan
Demuth, Dirk
Bressler, Brian
GASTROENTEROLOGY, 2019, 156 (06) : S638 - S638
[8] Real World Experience With Vedolizumab as First-Line Therapy for the Treatment of Ulcerative Colitis
Ritter, Timothy E.
Mehta, Samantha A.
Van Anglen, Lucinda J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S439 - S439
[9] Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's Disease
Bressler, Brian
Yarur, Andres
Kopylov, Uri
Bassel, Marielle
Brett, Neil R.
Lissoos, Trevor
Lopez, Claudia
Natsios, Athanasios
Saha, Sumit
Kifnidi, Christina
Demuth, Dirk
Patel, Haridarshan
Mantzaris, Gerassimos J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S373 - S373
[10] Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study
Bressler, B.
Yarur, A.
Kopylov, U.
Bassel, M.
Brett, N.
Colby, C.
Lopez, C.
Saha, S.
Kifnidi, C.
Agboton, C.
Adsul, S.
Demuth, D.
Luo, M.
Wang, S.
Mantzaris, G. J.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S381 - S382

← 1 2 3 4 5 →